State Street’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

State Street’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,039	Closed	-$17K	–	4020
2020 Q4	$17K	Sell	24,039 -2,455	-9%	-$5.23K	﹤0.01%	3873
2020 Q3	$60K	Sell	26,494 -1,691	-6%	-$4.83K	﹤0.01%	3744
2020 Q2	$101K	Sell	28,185 -14,653	-34%	-$52.9K	﹤0.01%	3659
2020 Q1	$163K	Sell	42,838 -62,210	-59%	-$205K	﹤0.01%	3589
2019 Q4	$316K	Buy	+105,048	New	+$273K	﹤0.01%	3579

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

State Street's BMY.RT Position: Q1 2021 in Review

State Street sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 24,039 shares — an estimated $17K sold.

State Street first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $316K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

State Street reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
State Street sold 24,039 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $17K.
State Street first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
State Street's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $316K in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on State Street's 13F filing for Q1 2021, filed 17 May 2021.